Table 1 Proportion of patients exacerbating during the follow-up period, with patients categorised by exacerbation history and eosinophil count
Patients (%) | Group 1 Low exacerbations and high eosinophils | Group 2 High exacerbations and high eosinophils | Group 3 Low exacerbations and low eosinophils | Group 4 High exacerbations and low eosinophils | Total |
|---|---|---|---|---|---|
Overall population | (N = 190) | (N = 53) | (N = 158) | (N = 29) | (N = 430) |
No exacerbation | 137 (72.1) | 27 (50.9) | 117 (74.1) | 15 (51.7) | 296 (68.8) |
One or more exacerbation | 41 (21.6) | 26 (49.1) | 35 (22.2) | 13 (44.8) | 115 (26.7) |
Missing values | 12 (6.3) | 0 | 6 (3.8) | 1 (3.4) | 19 (4.4) |
LABA/LAMA fixed–dose combination group | (N = 50) | (N = 4) | (N = 57) | (N = 2) | (N = 113) |
No exacerbation | 43 (86.0) | 2 (50.0) | 48 (84.2) | 1 (50.0) | 94 (83.2) |
One or more exacerbation | 5 (10.0) | 2 (50.0) | 9 (15.8) | 1 (50.0) | 17 (15.0) |
Missing values | 2 (4.0) | 0 | 0 | 0 | 2 (1.8) |
Triple therapy | (N = 140) | (N = 49) | (N = 101) | (N = 27) | (N = 317) |
No exacerbation | 94 (67.1) | 25 (51.0) | 69 (68.3) | 14 (51.9) | 202 (63.7) |
One or more exacerbation | 36 (25.7) | 24 (49.0) | 26 (25.7) | 12 (44.4) | 98 (30.9) |
Missing values | 10 (7.1) | 0 | 6 (5.9) | 1 (3.7) | 17 (5.4) |